← daily scanner dashboard

#5 XNCR — Xencor Inc

B_VCP_DEVELOPING | as of 2026-10-02 | automated relative priority, not a published Minervini point formula

Relative priority60.00
RS rating96.68
Fundamental strength75.00
VCP score79.37
Pivot distance3.35%
AV confirmation80.00%complete
Technical chart for XNCR

Trend Template

price_above_sma150_and_sma200PASS
sma150_above_sma200PASS
sma200_rising_1mPASS
sma50_above_sma150_and_sma200PASS
price_above_sma50PASS
price_at_least_30pct_above_52w_lowPASS
price_within_25pct_of_52w_highPASS
rs_rating_at_least_70PASS

Trend Template metrics

close24.84
sma5024.18
sma15016.74
sma20015.88
sma200_1m_ago14.96
pct_above_52w_low139.42
pct_below_52w_high18.85
rs_rating96.68

VCP conditions

coherent_contraction_sequencePASS
enough_contractionsPASS
successive_ranges_inside_firstPASS
successive_depths_contractingPASS
final_contraction_tightPASS
base_depth_okPASS
resistance_area_tightFAIL
volume_dryupFAIL
atr_contractingPASS
price_tightFAIL
near_pivotPASS

VCP metrics

num_contractions2.00
contraction_depths_pct[19.39, 9.32]
depth_ratios_vs_prior[0.481]
target_depth_ratio_roughly_half0.50
max_allowed_depth_ratio0.80
base_high28.98
base_low23.36
base_depth_pct19.39
base_duration_weeks4.30
resistance_spread_pct11.32
volume_dryup_ratio_10d_vs_50d0.96
atr_pct_recent4.43
atr_pct_prior6.22
atr_contraction_ratio0.71
tight_10d_range_pct13.07
raw_contraction_count12.00
raw_depths_pct[9.77, 15.41, 13.17, 23.09, 9.37, 7.59, 13.06, 15.31, 12.36, 15.7, 19.39, 9.32]
final_trough_age_bars5.00
selection_reasoncoherent_current_sequence
pivot_price25.70
distance_to_pivot_pct3.35
vcp_score_pct79.37
is_vcp_candidatePASS
breakout_on_volumeFAIL

Price / volume

return_1m_pct-7.66
return_3m_pct66.82
return_6m_pct93.91
return_12m_pct109.97
weighted_12m_momentum32.59
range_10d_pct13.07
range_20d_pct14.83
avg_volume_50d1.33M
dollar_volume_50d33.04M
up_down_volume_ratio_50d1.24
accumulation_days_20d1.00
distribution_days_20d4.00

Fundamental overlay criteria

eps_growth_minimumPASS
sales_growth_positive_or_betterPASS
core_data_coveragePASS
eps_acceleratingPASS
sales_acceleratingPASS
gross_margin_improving—
operating_margin_improvingPASS

Minervini-oriented SEC fundamentals

eps_growth_yoy_pct29.27
eps_previous_q_yoy_growth_pct-159.09
eps_acceleration_pts188.36
eps_annual_growth_pct65.36
eps_cagr_3y_pct—
sales_growth_yoy_pct17.46
sales_previous_q_yoy_growth_pct-86.20
sales_acceleration_pts103.66
sales_annual_growth_pct13.65
sales_cagr_3y_pct-8.62
gross_margin_pct—
operating_margin_pct-72.37
pretax_margin_pct-42.79
net_margin_pct-42.42
gross_margin_yoy_change_pts—
operating_margin_yoy_change_pts3.70
roe_latest_fy_pct-14.00
current_ratio6.39
debt_to_equity_pct20.84
cash_to_debt0.43
shares_outstanding—
adjusted_eps_growth_yoy_pct—
earnings_surprise_pct—
eps_estimate_revision_30d_pct—
analyst_count—
institutional_ownership_pct—
institutional_qoq_change_pct—
management_guidance_revision_pct—

SEC data quality

core_coverage_pct90.00
missing_core_metrics["shares_outstanding"]
selected_sec_tags{"accounts_payable": "us-gaap:AccountsPayableCurrent", "accounts_receivable": "us-gaap:AccountsReceivableNetCurrent", "capex": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "cash": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "cost_of_revenue": null, "current_assets": "us-gaap:AssetsCurrent", "current_liabilities": "us-gaap:LiabilitiesCurrent", "dividends_paid": null, "eps_basic": "us-gaap:EarningsPerShareBasic", "eps_diluted": "us-gaap:EarningsPerShareDiluted", "equity": "us-gaap:StockholdersEquity", "gross_profit": null, "inventory": null, "long_term_debt": "us-gaap:LongTermDebtNoncurrent", "long_term_debt_current": null, "net_income": "us-gaap:NetIncomeLoss", "operating_cash_flow": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "operating_income": "us-gaap:OperatingIncomeLoss", "pretax_income": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "r_and_d": "us-gaap:ResearchAndDevelopmentExpense", "revenue": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "sga": "us-gaap:GeneralAndAdministrativeExpense", "share_repurchases": null, "shares_outstanding": "dei:EntityCommonStockSharesOutstanding", "short_term_debt": "us-gaap:DebtCurrent", "short_term_investments": "us-gaap:MarketableSecuritiesCurrent", "stock_based_comp": "us-gaap:ShareBasedCompensation", "total_assets": "us-gaap:Assets", "total_liabilities": "us-gaap:Liabilities", "weighted_avg_diluted_shares": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"}
unavailable_canonical_concepts["cost_of_revenue", "dividends_paid", "gross_profit", "inventory", "long_term_debt_current", "share_repurchases"]
warnings["Standalone Q4 income/EPS can be absent because 10-K statements are annual.", "Company-specific extension tags are not returned by CompanyFacts.", "Non-GAAP EPS, guidance, 13F ownership, Form 4 activity, and analyst estimates are separate modules."]

Reporting periods

latest_quarter_end2026-06-30
latest_quarter_filed2026-08-05
latest_fiscal_year_end2025-12-31
latest_balance_sheet_end2026-06-30

Company metadata

symbolXNCR
cik1.33M
company_nameXencor Inc
exchange—
sic2,834
sic_descriptionPharmaceutical Preparations
fiscal_year_end1,231
as_of2026-10-04
sourceSEC EDGAR CompanyFacts + Submissions

Alpha Vantage enrichment

latest_reported_date2026-08-05
latest_reported_eps-0.29
latest_estimated_eps-0.82
latest_earnings_surprise_pct64.63
avg_earnings_surprise_4q_pct27.65
positive_earnings_surprises_4q3.00
earnings_surprise_quarters_available4.00
estimate_period2027-12-31
analyst_count_eps—
analyst_count_revenue—
eps_estimate_avg—
revenue_estimate_avg—
estimate_revision.eps_estimate_revision_up_trailing_7_days0.00
estimate_revision.eps_estimate_revision_up_trailing_30_days5.00
estimate_revision.eps_estimate_revision_down_trailing_30_days6.00
eps_revision_up_30d5.00
eps_revision_down_30d6.00
eps_revision_net_up_30d-1.00
institutional.total_institutional_holders244.00
institutional.total_institutional_shares92.04M
institutional.holders_with_increased_holdings118.00
institutional.holders_with_decreased_holdings90.00
institutional.holders_with_unchanged_holdings36.00
institutional_holder_rows244.00
institutional_total_shares92.04M
endpoints_returned["EARNINGS", "EARNINGS_ESTIMATES", "INSTITUTIONAL_HOLDINGS"]

Alpha Vantage confirmation screen

latest_earnings_surprise_positivePASS
average_4q_earnings_surprise_positivePASS
positive_surprise_quartersPASS
analyst_coverage_present—
eps_revision_breadth_nonnegative_30dFAIL
institutional_sponsorship_presentPASS

Alpha Vantage screen summary

statuscomplete
confirmation_score_pct80.00
available_criteria5.00
noteInformational post-Exp0 confirmation only; not part of validated Exp0 selection/ranking.

Alpha Vantage endpoint status

EARNINGScache_available
EARNINGS_ESTIMATEScache_available
INSTITUTIONAL_HOLDINGScache_available

Accepted VCP contractions

peak_datepeak_pricetrough_datetrough_pricedepth_pctdepth_ratio_vs_priorbars
2026-09-0228.982026-09-1523.3619.39—8.00
2026-09-2225.702026-09-2523.309.320.483.00

Recent SEC filings

formfiling_dateaccession_numberprimary_document
10-Q2026-08-050001326732-26-000056xncr-20260630.htm
8-K2026-08-050001326732-26-000055xncr-20260805.htm
8-K2026-07-290001326732-26-000049xncr-20260729.htm
8-K2026-06-180001326732-26-000045xncr-20260616.htm
10-Q2026-05-060001326732-26-000043xncr-20260331.htm
8-K2026-05-060001326732-26-000042xncr-20260506.htm
8-K2026-05-050001326732-26-000036xncr-20260504.htm
8-K2026-04-270001326732-26-000030xncr-20260423.htm
8-K2026-03-090001326732-26-000023xncr-20260304.htm
8-K2026-03-040001326732-26-000021xncr-20260304.htm
10-K2026-02-250001326732-26-000015xncr-20251231.htm
8-K2026-02-250001326732-26-000014xncr-20260225.htm

SEPA factors not covered by SEC + Yahoo

These remain manual or require another provider/module and are deliberately not guessed: